HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goetz, C. G. Articles by Klawans, H. L. Search for Related Content PubMed PubMed Citation Articles by Goetz, C. G. Articles by Klawans, H. L.

Bupropion in Parkinson's disease

From the Department of Neurological Sciences. Rush-Preshyterian St. Lukes Medical Center. Chicago, IL.

Bupropion is an antidepressant, thought to be an indirect dopaminergic agonist. No significant sympathomimetic, anticholinergic, or MA0 inhibitor effects have been reported. We evaluated this drug in 20 patients with idiopathic Parkinson's disease. Parkinsonism lessened by at least 30% (Northwestern University Disability Scale or Modified New York University Parkinson's Disease Scale) in half the patients. Depression, present in 12 of 20, was alleviated in only 5. Bupropion is mildly efficacious in Parkinson's disease, although side effects were frequent and were dose-limiting in five patients.

Address correspondence and reprint requests Dr. Goetz. Department of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, 1725 W. Harrison, Chicago, IL 60612.

This work was supported by Burroughs-Wellcome Pharmaceuticals. Triangle Park, NC, and the United Parkinson Foundation and Boothroyd Foundation, Chicago, IL. Dr. Goetz is the recipient of an NINCDS Teacher-Investigator Award.

Presented in part at the thirty-fifth annual meeting of the American Academy of Neurology, San Diego, CA. April 1983.

Accepted for publication December 12, 1989.

This article has been cited by other articles:

				B. K. Madras, M. A. Fahey, M. Goulet, Z. Lin, J. Bendor, C. Goodrich, P. C. Meltzer, D. R. Elmaleh, E. Livni, A. A. Bonab, et al. Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 570 - 585. [Abstract] [Full Text] [PDF]

				C. H. Adler and M. J. Thorpy Sleep issues in Parkinson's disease Neurology, June 28, 2005; 64(12_suppl_3): S12 - S20. [Abstract] [Full Text] [PDF]

				A. F. G. Leentjens Depression in Parkinson's Disease: Conceptual Issues and Clinical Challenges J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 120 - 126. [Abstract] [PDF]

				M. Menza, H. Marin, K. Kaufman, M. Mark, and M. Lauritano Citalopram Treatment of Depression in Parkinson's Disease: The Impact on Anxiety, Disability, and Cognition J Neuropsychiatry Clin Neurosci, August 1, 2004; 16(3): 315 - 319. [Abstract] [Full Text] [PDF]

				L. Marsh, J. R. Williams, M. Rocco, S. Grill, C. Munro, and T. M. Dawson Psychiatric comorbidities in patients with Parkinson disease and psychosis Neurology, July 27, 2004; 63(2): 293 - 300. [Abstract] [Full Text] [PDF]

				M. J. Hansard, L. A. Smith, M. J. Jackson, S. C. Cheetham, and P. Jenner Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 952 - 958. [Abstract] [Full Text] [PDF]

				S M Boesch, G K Wenning, G Ransmayr, and W Poewe Dystonia in multiple system atrophy J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 300 - 303. [Abstract] [Full Text] [PDF]

				M. S. Okun and R. L. Watts Depression associated with Parkinson's disease: Clinical features and treatment Neurology, February 1, 2002; 58(90001): S63 - 70. [Abstract] [Full Text]